|
1
|
Kirkali Z, Chan T, Manoharan M, Algaba F,
Busch C, Cheng L, Kiemeney L, Kriegmair M, Montironi R, Murphy WM,
et al: Bladder cancer: Epidemiology, staging and grading, and
diagnosis. Urology. 66 (6 Suppl 1):S4–S34. 2005.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Audenet F, Attalla K and Sfakianos JP: The
evolution of bladder cancer genomics: What have we learned and how
can we use it? Urol Oncol. 36:313–320. 2018.PubMed/NCBI View Article : Google Scholar
|
|
3
|
van den Bosch S and Alfred Witjes J:
Long-term cancer-specific survival in patients with high-risk,
non-muscle-invasive bladder cancer and tumour progression: A
systematic review. Eur Urol. 60:493–500. 2011.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Babjuk M, Böhle A, Burger M, Capoun O,
Cohen D, Compérat EM, Hernández V, Kaasinen E, Palou J, Rouprêt M,
et al: EAU guidelines on non-muscle-invasive urothelial carcinoma
of the bladder: Update 2016. Eur Urol. 71:447–461. 2017.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Martin-Doyle W, Leow JJ, Orsola A, Chang
SL and Bellmunt J: Improving selection criteria for early
cystectomy in high-grade t1 bladder cancer: A meta-analysis of
15,215 patients. J Clin Oncol. 33:643–650. 2015.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Kluth LA, Black PC, Bochner BH, Catto J,
Lerner SP, Stenzl A, Stenzl A, Sylvester R, Vickers AJ, Xylinas E
and Shariat SF: Prognostic and prediction tools in bladder cancer:
A comprehensive review of the literature. Eur Urol. 68:238–253.
2015.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Sylvester RJ, van der Meijden AP,
Oosterlinck W, Witjes JA, Bouffioux C, Denis L, Newling DW and
Kurth K: Predicting recurrence and progression in individual
patients with stage Ta T1 bladder cancer using EORTC risk tables: A
combined analysis of 2596 patients from seven EORTC trials. Eur
Urol. 49:466–477. 2006.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Fernandez-Gomez J, Madero R, Solsona E,
Unda M, Martinez-Piñeiro L, Gonzalez M, Portillo J, Ojea A, Pertusa
C, Rodriguez-Molina J, et al: Predicting nonmuscle invasive bladder
cancer recurrence and progression in patients treated with bacillus
Calmette-Guerin: The CUETO scoring model. J Urol. 182:2195–2203.
2009.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Orsola A, Palou J and Solsona E: High-risk
nonmuscle invasive bladder cancer. Hematol Oncol Clin North Am.
29:227–236, viii. 2015.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Xylinas E, Kent M, Kluth L, Pycha A,
Comploj E, Svatek RS, Lotan Y, Trinh QD, Karakiewicz PI, Holmang S,
et al: Accuracy of the EORTC risk tables and of the CUETO scoring
model to predict outcomes in non-muscle-invasive urothelial
carcinoma of the bladder. Br J Cancer. 109:1460–1466.
2013.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Hinotsu S, Akaza H, Naito S, Ozono S,
Sumiyoshi Y, Noguchi S, Yamaguchi A, Nagamori S, Terai A, Nasu Y,
et al: Maintenance therapy with bacillus Calmette-Guérin Connaught
strain clearly prolongs recurrence-free survival following
transurethral resection of bladder tumour for non-muscle-invasive
bladder cancer. BJU Int. 108:187–195. 2011.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Gontero P, Sylvester R, Pisano F, Joniau
S, Vander Eeckt K, Serretta V, Larré S, Di Stasi S, Van Rhijn B,
Witjes AJ, et al: Prognostic factors and risk groups in T1G3
non-muscle-invasive bladder cancer patients initially treated with
Bacillus Calmette-Guérin: Results of a retrospective multicenter
study of 2451 patients. Eur Urol. 67:74–82. 2015.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Patschan O, Holmäng S, Hosseini A,
Liedberg F, Ljungberg B, Malmström PU, Rosell J and Jahnson S: Use
of bacillus Calmette-Guérin in stage T1 bladder cancer: Long-term
observation of a population-based cohort. Scand J Urol. 49:127–132.
2015.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Spencer BA, McBride RB, Hershman DL, Buono
D, Herr HW, Benson MC, Gupta-Mohile S and Neugut AI: Adjuvant
intravesical bacillus Calmette-Guérin therapy and survival among
elderly patients with non-muscle-invasive bladder cancer. J Oncol
Pract. 9:92–98. 2013.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Witjes JA, Palou J, Soloway M, Lamm D,
Kamat AM, Brausi M, Persad R, Buckley R, Colombel M and Böhle A:
Current clinical practice gaps in the treatment of intermediate-
and high-risk non-muscle-invasive bladder cancer (NMIBC) with
emphasis on the use of bacillus Calmette-Guérin (BCG): Results of
an international individual patient data survey (IPDS). BJU Int.
112:742–750. 2013.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Lenis AT, Donin NM, Litwin MS, Saigal CS,
Lai J, Hanley JM, Konety BR and Chamie K: Urologic Diseases in
America Project: Association between number of endoscopic
resections and utilization of bacillus Calmette-Guérin therapy for
patients with high-grade, non-muscle-invasive bladder cancer. Clin
Genitourin Cancer. 15:e25–e31. 2017.
|
|
17
|
Kluth LA, Xylinas E, Crivelli JJ, Passoni
N, Comploj E, Pycha A, Chrystal J, Sun M, Karakiewicz PI, Gontero
P, et al: Obesity is associated with worse outcomes in patients
with T1 high grade urothelial carcinoma of the bladder. J Urol.
190:480–486. 2013.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Chamie K, Ballon-Landa E, Daskivich TJ,
Bassett JC, Lai J, Hanley JM, Konety BR, Litwin MS and Saigal CS:
Urologic Diseases in America Project: Treatment and survival in
patients with recurrent high-risk non-muscle-invasive bladder
cancer. Urol Oncol. 33:20.e9–20.e17. 2015.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Baltacı S, Bozlu M, Yıldırım A, Gökçe Mİ,
Tinay İ, Aslan G, Can C, Türkeri L, Kuyumcuoğlu U and Mungan A:
Significance of the interval between first and second transurethral
resection on recurrence and progression rates in patients with
high-risk non-muscle-invasive bladder cancer treated with
maintenance intravesical bacillus Calmette-Guérin. BJU Int.
116:721–726. 2015.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Kikuchi E, Fujimoto H, Mizutani Y, Okajima
E, Koga H, Hinotsu S, Shinohara N, Oya M and Miki T: Cancer
Registration Committee of the Japanese Urological Association:
Clinical outcome of tumor recurrence for Ta, T1 non-muscle invasive
bladder cancer from the data on registered bladder cancer patients
in Japan: 1999-2001 report from the Japanese urological
association. Int J Urol. 16:279–286. 2009.PubMed/NCBI View Article : Google Scholar
|
|
21
|
Grimm MO, Steinhoff C, Simon X,
Spiegelhalder P, Ackermann R and Vogeli TA: Effect of routine
repeat transurethral resection for superficial bladder cancer: A
long-term observational study. J Urol. 170:433–437. 2003.PubMed/NCBI View Article : Google Scholar
|
|
22
|
Jahnson S, Wiklund F, Duchek M, Mestad O,
Rintala E, Hellsten S and Malmström PU: Results of second-look
resection after primary resection of T1 tumour of the urinary
bladder. Scand J Urol Nephrol. 39:206–201. 2005.PubMed/NCBI View Article : Google Scholar
|
|
23
|
Lazica DA, Roth S, Brandt AS, Böttcher S,
Mathers MJ and Ubrig B: Second transurethral resection after Ta
high-grade bladder tumor: A 4.5-year period at a single university
center. Urol Int. 92:131–135. 2014.PubMed/NCBI View Article : Google Scholar
|
|
24
|
Branchereau J, Larue S, Vayleux B, Karam
G, Bouchot O and Rigaud J: Prognostic value of the lymphovascular
invasion in high-grade stage pT1 bladder cancer. Clin Genitourin
Cancer. 11:182–188. 2013.PubMed/NCBI View Article : Google Scholar
|
|
25
|
Hernández V, De La Peña E, Martin MD,
Blázquez C, Diaz FJ and Llorente C: External validation and
applicability of the EORTC risk tables for non-muscle-invasive
bladder cancer. World J Urol. 29:409–414. 2011.PubMed/NCBI View Article : Google Scholar
|
|
26
|
Ding W, Gou Y, Sun C, Xia G, Wang H, Chen
Z, Tan J, Xu K and Qiang D: Ki-67 is an independent indicator in
non-muscle invasive bladder cancer (NMIBC); combination of EORTC
risk scores and Ki-67 expression could improve the risk
stratification of NMIBC. Urol Oncol. 32:42.e13–e19. 2014.PubMed/NCBI View Article : Google Scholar
|
|
27
|
Liu B, Miyake H, Nishikawa M and Fujisawa
M: Expression profile of epithelial-mesenchymal transition markers
in non-muscle-invasive urothelial carcinoma of the bladder:
Correlation with intravesical recurrence following transurethral
resection. Urol Oncol. 33:110.e11–e18. 2015.PubMed/NCBI View Article : Google Scholar
|
|
28
|
Behnsawy HM, Miyake H, Abdalla MA, Sayed
MA, Ahmed Ael-F and Fujisawa M: Expression of cell cycle-associated
proteins in non-muscle-invasive bladder cancer: Correlation with
intravesical recurrence following transurethral resection. Urol
Oncol. 29:495–501. 2011.PubMed/NCBI View Article : Google Scholar
|
|
29
|
Yuk HD, Jeong CW, Kwak C, Kim HH and Ku
JH: Elevated neutrophil to lymphocyte ratio predicts poor prognosis
in non-muscle invasive bladder cancer patients: Initial
intravesical bacillus calmette-guerin treatment after transurethral
resection of bladder tumor setting. Front Oncol.
8(642)2019.PubMed/NCBI View Article : Google Scholar
|
|
30
|
Passoni N, Gayed B, Kapur P, Sagalowsky
AI, Shariat SF and Lotan Y: Cell-cycle markers do not improve
discrimination of EORTC and CUETO risk models in predicting
recurrence and progression of non-muscle-invasive high-grade
bladder cancer. Urol Oncol. 34:485.e7–485.e14. 2016.PubMed/NCBI View Article : Google Scholar
|
|
31
|
Fahmy O, Khairul-Asri MG, Stenzl A and
Gakis G: Systemic anti-CTLA-4 and intravesical
Bacille-Calmette-Guerin therapy in non-muscle invasive bladder
cancer: Is there a rationale of synergism? Med Hypotheses.
92:57–58. 2016.PubMed/NCBI View Article : Google Scholar
|
